NCT06555640已完成2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous Injection of DR10624 in Subjects With Severe Hypertriglyceridemia
Zhejiang Doer Biologics Co., Ltd.35 个研究点 分布在 1 个国家目标入组 79 人开始时间: 2024年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 79
- 试验地点
- 35
- 主要终点
- Change of fasting TG
研究概览
简要总结
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the efficacy of DR10624 on fasting serum triglyceride (TG) levels after 12 weeks of treatment in subjects with severe hypertriglyceridemia (SHTG).
详细描述
The subjects will be randomly assigned to experimental groups and placebo-controlled groups. Each participant will be enrolled in only one cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 17 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Subjects or their legally acceptable representatives must be able to provide written informed consent, understand the procedures and methods of the study, and agree to comply with all protocol requirements.
- •2.Male or female, age of 18 to 75 years (inclusive) at screening.
- •3.Subjects must have a BMI of >19 kg/m2 and BMI of ≤45.0 kg/m2 , and body weight ≥50 Kg at screening.
- •4.During screening or within 1 week prior to screening, the TG levels should meet the following criteria: 4.80 mmol/L (425 mg/dL) ≤ fasting TG < 22.60 mmol/L (2000 mg/dL).
- •5.The average fasting TG level of Visit 2 and Visit 3 values must meet: 5.65 mmol/L (500 mg/dL) ≤fasting TG <22.60 mmol/L(2000 mg/dL); or the average fasting TG level of Visit 3 and Visit 3.1 values must meet the same criteria.
- •6.Subjects will able to accept rencommendation on therapeutic lifestyle modificationa and maintain a stable lifestyle for the duration of the study.
- •7.Subjects who are receiving statins, cholesterol-absorption inhibitor (CAI), fibrates, niacin ≥500 mg/day, or prescription omega-3 fish oil must have achieved a stable dose for at least 4 weeks before screening.
- •8.Subjects diagnosed with type 2 diabetes(T2DM) must have a glycosylated hemoglobin level at screening of<9.5%(80 mmol/mol）and treated with lifestyle modification or a stable doses of antidiabetic medications for at least 8 weeks prior to screening.
排除标准
- •1.Subjects with known familial hyperchylomicronemia (Fredrickson type 1) ,apo c-II deficiency,or familial β-lipoprotein dyslipidemia (Fredrickson type 3); or subjects with a high suspicion of having this three conditions.
- •2.Subjects who have lost ≥5% of body weight within 3 months prior to screening, or who lose ≥5% of body weight during screening, or who plan to lose body weight during the study.
- •3.Subjects with type 1 diabetes, or nephrotic syndrome.
- •4.Subjects with cirrhosis, alcoholic liver disease, liver failure, liver cancer, or autoimmune hepatitis.
- •5.Subjects type 2 diabetes with a duration of less than 12 weeks or with severe complications.
- •6.Uncontrolled hypertension at screening, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg under medication conditions.
- •7.Subjects with an active or untreated malignancy or who have been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for <5 years prior to screening.
- •8.Subjects with a family or personal history of medullary thyroid carcinoma (MTC),multiple endocrine neoplasia syndrome type 2 (MEN2),severe active or unstable major depressive disorder (MDD), or other serious mental disorders (such as schizophrenia, bipolar disorder, or other severe mood or anxiety disorders) or suicidal.
- •9.Subjects with a known clinically significant gastric emptying abnormality (e.g. severe diabetic gastroparesis), and who have undergone or plan to undergo gastric bypass surgery or gastric banding surgery during the study, or those who chronically take drugs that directly affect GI motility.
- •10.New York Heart Association Functional Classification III or IV CHF.
- •11.In the opinion of the investigator, the subjects are likely to require concurrent treatment with systemic glucocorticoids during the trial due to comorbidities.
- •12.Subjects with a history of acute pancreatitis within 1 year prior to screening, or a history of chronic pancreatitis, or symptomatic of gallbladder disease (e.g. choledocholithiasis, gallbladder multiple stones, unless treated with cholecystectomy).
- •13.Subjects with any of the following cardiovascular (CV) conditions within 6 months prior to screening: acute myocardial infarction, cerebral hemorrhage or cerebral infarction (except lacunar infarction), or hospitalization due to CHF, unstable angina pectoris or transient ischemic attack, or cardiac surgery such as percutaneous coronary intervention and coronary artery bypass grafting,or subjects who have been treated with GLP-1R agonists, or have participated in a clinical study involving GLP-1R and received the study drug within 6 months prior to screening.
- •14.Subjects who have undergone large-sized surgery,have been treated with GCGR or multiple target point and agonists containing FGF-21R targets;have been treated with SiRNA type and monoclonal antibody type of PCSK9 inhibitors;or who have participated in a clinical study related to above all the types of drug within 3 months prior to screening.
- •15.Subjects with severe trauma, severe infection who have not recoveredwithin 4 weeks prior to screening,who have been treated with DPP-4 inhibitors, or have participated in a clinical study related to DPP-4 inhibitors and received the study product;who have undergone lipid apheresis or plasma exchange treatment within the last 4 weeks or plan to undergo apheresis or plasma exchange during the study period.
- •16.Subjects with hyperthyroidism or hypothyroidism who have the stable dose of therapeutic drugs less than 3 months prior to screening.
- •17.Subjects with Cushing's syndrome or who have continuously or cumulatively used systemic glucocorticoids for more than 14 days within 6 months before screening, Inhaled or topical corticosteroids are permitted.
- •18.Subjects who do not agree to discontinue medications, supplements, or nutraceuticals that have lipid-altering effects other than those specified in the protocol.
- •19.Subjects who are taking insulin or second-generation antipsychotics and cannot stop taking them.
- •20.Serum calcitonin ≥20 ng/L (pg/mL) in subjects with eGFR≥60 mL/min/1.73 m2 , or serum calcitonin ≥35 ng/L (pg/mL) in subjects with eGFR <60 mL/min/1.73 m
- •21.Alanine aminotransferase>3.0 × upper limit of normal value (ULN) and/or aspartate aminotransferase>3.0 × ULN and/or total bilirubin>1.5 × ULN.
- •22.Glomerular filtration rate eGFR < 45 mL/min/1.73 m2
- •23.TSH > upper normal limit or < lower normal limit.
- •24.Serum amylase or lipase > 2.0 × ULN.
- •25.Hemoglobin < 110 g/L (males) or < 100 g/L (females).
- •26.Test positive for Human Immunodeficiency Virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV), HBV and HCV determined by antibodies first and, if positive, by DNA/ribonucleic acid (RNA).
- •27.Clinically significant 12-lead electrocardiogram (ECG) abnormalities at the time of screening.
- •28.History of drug abuse or excessive alcohol consumption within 3 months prior to screening.
- •29.Presence of potential allergies to the study drug, its ingredients, or drugs of the same class.
- •30.Pregnant or lactating women;as well as men and women of childbearing potential who are unwilling to prevent pregnancy throughout the study and within the specified time after the study.
- •31.Blood donation and/or blood loss ≥400 mL, or bone marrow donation within 3 months prior to screening.
- •32.Subjects in which the investigator deems to that there are any other factors may affect the efficacy or safety evaluation of this study(including medical, psychological, social, or geographical considerations) .
研究组 & 干预措施
Cohort 2: DR10624 injection
Experimental
DR10624 injection administered weekly (QW)
干预措施: DR10624 Injection (Drug)
Cohort 1: DR10624 injection
Experimental
DR10624 injection administered weekly (QW)
干预措施: DR10624 Injection (Drug)
Cohort 1: Placebo
Placebo Comparator
Placebo administered weekly (QW)
干预措施: Placebo (Drug)
Cohort 2: Placebo
Placebo Comparator
Placebo administered weekly (QW)
干预措施: Placebo (Drug)
Cohort 3: DR10624 injection
Experimental
DR10624 injection administered weekly (QW)
干预措施: DR10624 Injection (Drug)
Cohort 3: Placebo
Placebo Comparator
Placebo administered weekly (QW)
干预措施: Placebo (Drug)
结局指标
主要结局
Change of fasting TG
时间窗: From baseline to Week 12
The percentage change of fasting TG in all the participants from baseline to Week 12
次要结局
- Change of lipid profile and lipoprotein profile(From baseline to Week 12)
- Number of participants whose fasting TG lowered by at least 50%(From baseline to Week 12)
- Change of glycosylated hemoglobin (HbA1C)(From baseline to Week 12)
- Change of liver fat content(From baseline to week 12)
- Change of liver stiffness measurements (LSM)(From baseline to week 12)
- Anti-drug antibody（ADA）(through study completion, up to 17 weeks)
- Change of controlled decay index (CAP)(From baseline to week 12)
- Incidence and severity of adverse events(through study completion, up to 17 weeks)
- Pharmacokinetic Ctrough blood concentration of DR10624(through study completion, up to 17 weeks)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
不适用
aminar airflow in severe asthma for exacerbation reductioAsthmaISRCTN46346208Queen Alexandra Hospital (UK)240
已完成
2 期
Investigation Of A New Medication (GW642444) In Asthmatic PatientsAsthmaNCT00354874GlaxoSmithKline28
已完成
3 期
Clinical study to assess the efficacy and safety of Silexan in patients with depressioMild to moderate major depressive episodeMental and Behavioural DisordersISRCTN36202964Dr Willmar Schwabe (Germany)577
已完成
不适用
Dietary food supplement Helinorm containing L.reuteri DSM 17648 in eradication treatment inH.pylori-positive patients with functional dyspepsia?onfirmed diagnosis of functional dyspepsia according to Rome IV criteria and presence of H. pylori infection according to 13C-UBTDigestive SystemFunctional dyspepsiaISRCTN20716052izhny Novgorod Chemical and Pharmaceutical Plant Joint Stock Company (Nizhpharm JSC)172
已完成
3 期
Study of mirtazapine for agitation in dementiaISRCTN17411897niversity of Sussex247
相关资讯
Doer Biologics Completes Phase 2 Enrollment for Novel Tri-Specific Agonist Targeting Severe Hypertriglyceridemia- Doer Biologics has completed enrollment of 79 patients in its Phase 2 clinical trial evaluating DR10624, a first-in-class tri-specific agonist targeting FGF21R, GCGR, and GLP-1R for severe hypertriglyceridemia.
- The randomized, placebo-controlled study will evaluate three dose levels of DR10624 in patients with fasting triglycerides ≥500 mg/dL over a 12-week period, with topline data expected in Q3 2025.
- Preclinical and early clinical data suggest DR10624 demonstrates significant potency in reducing triglycerides, normalizing blood lipids, and improving liver function, potentially addressing serious complications like acute pancreatitis and ASCVD.last yearDoer Bio Doses First Patient in Phase 2 Trial of DR10624 for Severe Hypertriglyceridemia- Doer Biologics has dosed the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia (SHTG).
- DR10624 is a first-in-class tri-agonist targeting FGF21R, GLP-1R, and GCGR, designed for balanced activity in treating metabolic diseases.
- The Phase 2 trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DR10624 in adult SHTG patients.
- The study aims to identify the optimal dose of DR10624 for Phase 3 trials, addressing the heightened risk of pancreatitis and cardiovascular disease in SHTG patients.last year